HCT-CI — Haematopoietic Cell Transplant Comorbidity Index
Predicts non-relapse mortality after allogeneic haematopoietic stem cell transplantation. Score 0–29.
Score interpretation
HCT-CI 0. 2-year NRM ~14–17%.
→ Standard conditioning regimen appropriate. Proceed with planned allo-SCT.
HCT-CI 1–2. 2-year NRM ~21–28%.
→ Discuss increased NRM risk with patient. Optimise comorbidities pre-transplant. Consider reduced-intensity conditioning (RIC).
HCT-CI ≥3. 2-year NRM ~36–50%.
→ Careful risk-benefit discussion. RIC or non-myeloablative conditioning preferred. Transplant in specialist centre. Consider clinical trial or alternative strategy.
Interpretation bands for the HCT-CI. Apply clinical judgement and local guidance.
References
- Sorror ML et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
Related
Curated clinical cross-links plus same-class fallbacks.
- ADHERE Algorithm for Acute Decompensated Heart Failure · Risk Stratification
- TIMI Risk Index for STEMI · Risk Stratification
- LACE Index for Readmission Risk · Risk Stratification
- Charlson Comorbidity Index (CCI) — Detailed · Risk Stratification
- GI-BLEED Score for Upper GI Bleeding · Risk Stratification
- San Francisco Syncope Rule (SFSR) · Risk Stratification
- Sodium Cromoglicate Nasal Spray · Mast Cell Stabiliser — Allergic Rhinitis
- Olopatadine · H1 antihistamine + mast cell stabiliser
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Crizanlizumab · P-selectin Inhibitor — Sickle Cell Disease
- Voxelotor · Haemoglobin S Polymerisation Inhibitor — Sickle Cell Disease
- Mosunetuzumab · CD20×CD3 Bispecific T-Cell Engager
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.